239 related articles for article (PubMed ID: 12704230)
1. Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling.
Paolocci N; Katori T; Champion HC; St John ME; Miranda KM; Fukuto JM; Wink DA; Kass DA
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5537-42. PubMed ID: 12704230
[TBL] [Abstract][Full Text] [Related]
2. Calcitonin gene-related peptide in vivo positive inotropy is attributable to regional sympatho-stimulation and is blunted in congestive heart failure.
Katori T; Hoover DB; Ardell JL; Helm RH; Belardi DF; Tocchetti CG; Forfia PR; Kass DA; Paolocci N
Circ Res; 2005 Feb; 96(2):234-43. PubMed ID: 15591228
[TBL] [Abstract][Full Text] [Related]
3. Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling.
Paolocci N; Saavedra WF; Miranda KM; Martignani C; Isoda T; Hare JM; Espey MG; Fukuto JM; Feelisch M; Wink DA; Kass DA
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10463-8. PubMed ID: 11517312
[TBL] [Abstract][Full Text] [Related]
4. Soluble guanylate cyclase is required for systemic vasodilation but not positive inotropy induced by nitroxyl in the mouse.
Zhu G; Groneberg D; Sikka G; Hori D; Ranek MJ; Nakamura T; Takimoto E; Paolocci N; Berkowitz DE; Friebe A; Kass DA
Hypertension; 2015 Feb; 65(2):385-92. PubMed ID: 25452469
[TBL] [Abstract][Full Text] [Related]
5. Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition.
Hashimoto T; Kim GE; Tunin RS; Adesiyun T; Hsu S; Nakagawa R; Zhu G; O'Brien JJ; Hendrick JP; Davis RE; Yao W; Beard D; Hoxie HR; Wennogle LP; Lee DI; Kass DA
Circulation; 2018 Oct; 138(18):1974-1987. PubMed ID: 30030415
[TBL] [Abstract][Full Text] [Related]
6. The HNO donor Angeli's salt offers potential haemodynamic advantages over NO or dobutamine in ischaemia-reperfusion injury in the rat heart ex vivo.
Chin KY; Michel L; Qin CX; Cao N; Woodman OL; Ritchie RH
Pharmacol Res; 2016 Feb; 104():165-75. PubMed ID: 26747404
[TBL] [Abstract][Full Text] [Related]
7. Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.
Sabbah HN; Tocchetti CG; Wang M; Daya S; Gupta RC; Tunin RS; Mazhari R; Takimoto E; Paolocci N; Cowart D; Colucci WS; Kass DA
Circ Heart Fail; 2013 Nov; 6(6):1250-8. PubMed ID: 24107588
[TBL] [Abstract][Full Text] [Related]
8. Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure.
Asanoi H; Ishizaka S; Kameyama T; Ishise H; Sasayama S
J Cardiovasc Pharmacol; 1994 Feb; 23(2):268-74. PubMed ID: 7511757
[TBL] [Abstract][Full Text] [Related]
9. The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature.
Favaloro JL; Kemp-Harper BK
Cardiovasc Res; 2007 Feb; 73(3):587-96. PubMed ID: 17189622
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes.
Mehel H; Emons J; Vettel C; Wittköpper K; Seppelt D; Dewenter M; Lutz S; Sossalla S; Maier LS; Lechêne P; Leroy J; Lefebvre F; Varin A; Eschenhagen T; Nattel S; Dobrev D; Zimmermann WH; Nikolaev VO; Vandecasteele G; Fischmeister R; El-Armouche A
J Am Coll Cardiol; 2013 Oct; 62(17):1596-606. PubMed ID: 23810893
[TBL] [Abstract][Full Text] [Related]
11. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure.
Senzaki H; Smith CJ; Juang GJ; Isoda T; Mayer SP; Ohler A; Paolocci N; Tomaselli GF; Hare JM; Kass DA
FASEB J; 2001 Aug; 15(10):1718-26. PubMed ID: 11481219
[TBL] [Abstract][Full Text] [Related]
12. Myocyte nitric oxide synthase 2 contributes to blunted beta-adrenergic response in failing human hearts by decreasing Ca2+ transients.
Ziolo MT; Maier LS; Piacentino V; Bossuyt J; Houser SR; Bers DM
Circulation; 2004 Apr; 109(15):1886-91. PubMed ID: 15037528
[TBL] [Abstract][Full Text] [Related]
13. Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat.
Bendall JK; Damy T; Ratajczak P; Loyer X; Monceau V; Marty I; Milliez P; Robidel E; Marotte F; Samuel JL; Heymes C
Circulation; 2004 Oct; 110(16):2368-75. PubMed ID: 15466641
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the NO and HNO donating properties of diazeniumdiolates: primary amine adducts release HNO in Vivo.
Miranda KM; Katori T; Torres de Holding CL; Thomas L; Ridnour LA; McLendon WJ; Cologna SM; Dutton AS; Champion HC; Mancardi D; Tocchetti CG; Saavedra JE; Keefer LK; Houk KN; Fukuto JM; Kass DA; Paolocci N; Wink DA
J Med Chem; 2005 Dec; 48(26):8220-8. PubMed ID: 16366603
[TBL] [Abstract][Full Text] [Related]
15. Nitroxyl increases force development in rat cardiac muscle.
Dai T; Tian Y; Tocchetti CG; Katori T; Murphy AM; Kass DA; Paolocci N; Gao WD
J Physiol; 2007 May; 580(Pt.3):951-60. PubMed ID: 17331988
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of beta- but not alpha 1-mediated adrenergic responses in isolated hearts and cardiomyocytes by nitric oxide and 8-bromo cyclic GMP.
Ebihara Y; Karmazyn M
Cardiovasc Res; 1996 Sep; 32(3):622-9. PubMed ID: 8881523
[TBL] [Abstract][Full Text] [Related]
17. Increased contribution of alpha 1- vs. beta-adrenoceptor-mediated inotropic response in rats with congestive heart failure.
Sjaastad I; Schiander I; Sjetnan A; Qvigstad E; Bøkenes J; Sandnes D; Osnes JB; Sejersted OM; Skomedal T
Acta Physiol Scand; 2003 Apr; 177(4):449-58. PubMed ID: 12648162
[TBL] [Abstract][Full Text] [Related]
18. Chronic administration of the HNO donor Angeli's salt does not lead to tolerance, cross-tolerance, or endothelial dysfunction: comparison with GTN and DEA/NO.
Irvine JC; Kemp-Harper BK; Widdop RE
Antioxid Redox Signal; 2011 May; 14(9):1615-24. PubMed ID: 20849324
[TBL] [Abstract][Full Text] [Related]
19. Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae.
Irvine JC; Favaloro JL; Widdop RE; Kemp-Harper BK
Hypertension; 2007 Apr; 49(4):885-92. PubMed ID: 17309955
[TBL] [Abstract][Full Text] [Related]
20. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5.
Takimoto E; Belardi D; Tocchetti CG; Vahebi S; Cormaci G; Ketner EA; Moens AL; Champion HC; Kass DA
Circulation; 2007 Apr; 115(16):2159-67. PubMed ID: 17420342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
